Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus KENALOG 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus KENALOG 10.
EMFLAZA vs KENALOG-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also stabilizes lysosomal membranes and inhibits fibroblast proliferation.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
Intra-articular, intrabursal, or soft tissue injection: 10-40 mg (0.25-1 mL of 10 mg/mL) for large joints; 10 mg (0.25 mL) for small joints; repeat every 3-4 weeks if needed. Intralesional: 10-40 mg (0.25-1 mL) per lesion; maximum 1 mL per injection site; repeat every 1-2 weeks.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Category C
Category C
Corticosteroid
Corticosteroid